These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21700754)

  • 1. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
    Hong SJ; Choi SC; Ahn CM; Park JH; Kim JS; Lim DS
    Heart; 2011 Sep; 97(17):1425-32. PubMed ID: 21700754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.
    Hong SJ; Shim WJ; Choi JI; Joo HJ; Shin SY; Park SM; Lim SY; Lim DS
    Am J Cardiol; 2007 Dec; 100(11):1625-9. PubMed ID: 18036359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
    Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
    Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
    Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A
    Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
    Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J
    Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
    Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients.
    Terashima M; Kaneda H; Nasu K; Matsuo H; Habara M; Ito T; Tanaka N; Rathore S; Kinoshita Y; Kimura M; Ehara M; Suzuki Y; Suzuki T
    JACC Cardiovasc Interv; 2012 Feb; 5(2):182-90. PubMed ID: 22361603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
    Takagi H; Mizuno Y; Yamamoto H; Goto SN; Umemoto T;
    Hypertens Res; 2013 Apr; 36(4):368-73. PubMed ID: 23235712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
    Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
    Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
    Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y
    Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
    Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
    Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
    [No Abstract]   [Full Text] [Related]  

  • 16. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial.
    Waseda K; Ako J; Yamasaki M; Koizumi T; Sakurai R; Hongo Y; Koo BK; Ormiston J; Worthley SG; Whitbourn RJ; Walters DL; Meredith IT; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2011 Jun; 4(3):248-55. PubMed ID: 21586691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
    Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
    Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Ichikawa Y
    Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.